Your Position:Home>Products>Monoclonals/Polyclonals>Anti-Human CD38 Reference Antibody

Anti-Human CD38 Reference Antibody

  • Cat. No.:RB9THB691056
  • Price:Negotiable
  • Clicks:346

Product Detail

Product Parameters

FormLiquid
Host SpeciesHumanized
ClonalityMonoclonal
IsotypeIgG4-kappa
Purity>95% purity as determined by SDS-PAGE.
PurificationProtein A/G purified from cell culture supernatant.
Concentration1mg/ml
Endotoxin LevelPlease contact the lab for this information.
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Species ReactivityHuman
TargetCyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, T10, 2'-phospho-cyclic-ADP
Storage Buffer0.01M PBS, pH 7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Expression SystemMammalian Cells
Accession NumberP28907
BackgroundDaratumumab is human IgG1 monoclonal antibody to CD38, which is a transmembrane glycoprotein that is frequently overexpressed on cancer cells including multiple myeloma cells. The monoclonal antibody binds to the CD38 molecule and triggers cell apoptosis, probably as a result of antibody mediated cytotoxicity. Daratumumab has been evaluated in heavily pretreated patients with refractory multiple myeloma and shown overall response rates of higher than expected. Daratumumab was given accelerated approval in the United States in 2015 for use in multiple myeloma. Current indications are as therapy of patients with refractory multiple myeloma in combination with lenalidomide (or bortezomib) and dexamethasone or as monotherapy in patients who have failed at least three previous regimens. Daratumumab is available as a solution for intravenous infusion in single use vials of 100 mg in 5 mL or 400 mg in 20 mL (20 mg/mL). The recommended dose is 16 mg/kg intravenously every week for 8 to 9 weeks, and then every 2, 3 or 4 weeks based upon indications and other agents being used. Premedication with methylprednisolone is recommended. Side effects are common and can include infusion reactions, bone marrow suppression, fatigue, nausea and vomiting, diarrhea, muscle spasms, back pain, fever, cough, dyspnea, peripheral edema, peripheral neuropathy and upper respiratory infection. Rare, but potentially serious side effects include severe infusion reactions, neutropenia, thrombocytopenia and interference with cross matching and red blood cell antibody screening.
• Rapid induction of CD38 antigen on myeloid leukemia cells by all trans-retinoic acid., PMID:7690555
• Activation markers on peripheral blood T cells from patients with active or inactive systemic lupus erythematosus. Correlation with proliferative responses and production of IL-2., PMID:1812897
• Thymic hormone modulation of CD38 (T10) antigen on human cord blood lymphocytes., PMID:3315336
• Expression of activation antigens CD38 and CD71 is not clinically important in childhood acute lymphoblastic leukemia., PMID:8418378
• Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation., PMID:2319135
• A phenotypic study of cells from Burkitt lymphoma and EBV-B-lymphoblastoid lines and their relationship to cells in normal lymphoid tissues., PMID:2536003
• [Monoclonal antibodies ICO-20 against human thymocyte antigen T10]., PMID:3048431
Alternative NamesTAK-573, TEV-48573, 2254522-19-3
NoteFor research use only. Not suitable for clinical or therapeutic use.
For Research Use Only. Not for Diagnostic Procedures.

Related Products:
Total 33055 records,Divided into 1653 pages,The 1 pages | First Prev Next Last
Live Chat
  • Tel:
  • WeChat ID: 15898894496
  • Add Message
  • 9:00 AM – 6:00 PM